T1	Participants 819 944	postmenopausal women with advanced breast carcinoma who had disease progression after receipt of previous endocrine treatment
T2	Participants 1025 1070	319 (74.5%) patients in the fulvestrant group
T3	Participants 1075 1120	322 (76.1%) patients in the anastrozole group
